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Drug targetThe (3R)-hydroxyacyl-ACP dehydratase HadAB, involved in the biosynthetic pathway for mycolic acid
(MA) of Mycobacterium tuberculosis, catalyzes the third step in the fatty acid (FA) elongation cycle, which
is an ideal and actual target for anti-tubercular agent. Though HadAB is predicted to be a member of the
hotdog superfamily, it shares no sequence identity with typical hotdog fold isoenzyme FabZ. To charac-
terize the signiﬁcance of HadAB from the perspective of structural biology, large amount of pure HadAB
complex is required for biochemical characterization and crystallization. Here, we used a unique expres-
sion and puriﬁcation method. HadA and HadB were cloned separately and co-expressed in Escherichia coli.
After GST afﬁnity chromatography, two steps of anion exchange chromatography and gel ﬁltration, the
purity of the protein as estimated by SDS–PAGE was >95%. Using hanging-drop vapor-diffusion method,
crystals were obtained and diffracted X-rays to 1.75 Å resolution. The crystal belongs to space group
P41212, with unit-cell parameters a = b = 82.0 Å, c = 139.8 Å, a = b = c = 90.0.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction in Mtb: the b-ketoacyl-ACP synthetases (KasA and KasB, Rv2245Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb),
is the second most common cause of death due to a single infec-
tious pathogen with an enormous global medical burden [1,2].
The complicated cell envelope ofMtb contains many kinds of lipids
which play vital roles in the physiology and pathogenicity of this
bacterium [3,4]. Mycolic acids (MAs), 2-alkyl, 3-hydroxy
long-chain (C60–C90) fatty acids, constitute the major and speciﬁc
lipid component of the envelope. They either link covalently to
the cell wall peptidoglycan via the underlying arabinogalactan to
form Mycolic acid–Arabinogalactan-Peptidoglycan complex
(MAPc) or exist in the mycomembrane as trehalose mono- and
dimycolates [5]. This provides a thick layer of lipid in the cell wall
and protects the Mtb from dry environment, poisonous chemicals
and host’s immune system [6,7].
The biosynthetic pathway of this MAs involves two types of
fatty acid-synthesizing systems (FASs): the multifunctional FAS-I
and the dissociated FAS-II [8] (Fig. 1). The latter is composed of a
series of discrete soluble enzymes which act successively and
repetitively to elongate the FA chains produced by FAS-I [7].
There are four kinds of enzymes catalyze each cycle of elongationand Rv2246, respectively. Enzyme Classiﬁcation No.: 2.3.1.41),
the b-ketoacyl-ACP reductase (MabA, Rv1483. EC: 1.1.1.100), the
b-hydroxyacyl-ACP dehydratases (HadAB and HadBC,
Rv0635-Rv0636 and Rv0636-Rv0637. EC Number is not regis-
tered), and the trans-2-enoyl-ACP reductase (InhA, Rv1484. EC:
1.3.1.9). Deﬁciency or inactivation of anyone above will cease the
biosynthesis of MA and absence of these enzymes in human make
them very ideal and actual targets for drug discovery [9,10].
The (3R)-hydroxyacyl-ACP dehydratase HadAB, composed of
two subunits HadA (Rv0635) and HadB (Rv0636), catalyzes the
third step in the FA elongation cycle by dehydrating
b-hydroxyacyl-ACP to trans-2-enoyl-ACP, which is the last piece
to be identiﬁed in the mycobacterial FAS-II [11]. HadAB would take
part, like KasA, in the early FA elongation cycles, leading to the
formation of the intermediate-size (C32–C42) meromycolic
chains, while HadBC, like KasB, would elongate further the
intermediate-size meromycolic chains to full-size molecules
(C52–C64) during the late elongation cycles [11,12]. It has been ver-
iﬁed that NAS-21, NAS-91, some kinds of ﬂavonoids and an anti-TB
prodrug Thiacetazone (TAC) can inhibit the activity of HadB
(Rv0636) as well as the growth of bacteria at different levels by
mutation and overexpression methods [13–16]. Therefore HadAB
complex is a signiﬁcant drug target.
Though HadAB is predicted to be a member of hotdog super-
family, it resides only in Corynebacterineae and presents a different
Fig. 1. Biosynthetic pathway of mycolic acids in M. tuberculosis. AcpM: mycobacterial acyl-carrier-protein involved in FAS-II system.
Table 1
Summary of puriﬁcation conditions of HadAB.
Parameters GST afﬁnity HiTrap™ Q HP RESOURCE™ Q Superdex 75
Column volume 2 mL 5 mL 1 mL 24 mL
Buffer Buffer A (50 mM Tris–HCl, pH 8.0, 300 mM
NaCl and 10% (v/v) glycerol)
Buffer B (50 mM Tris–HCl, pH 8.0, 50 mM NaCl and 10% (v/v)
glycerol)
Buffer C (50 mM Tris–HCl, pH 8.0, 1 M NaCl and 10% (v/v)
glycerol)
Buffer D (50 mM Tris–HCl, pH
8.0, 150 mM NaCl, and 10% (v/
v) glycerol)
Sample volume About 150 mL 50 mL 50 mL Less than 500 lL
Flow rate 2 mL min1 1.5 mL min1 1.5 mL min1 0.5 mL min1
Washing volume 60–100 mL 10–15 mL 2–3 mL –
Elution mode After 30 lg mL1 Prescission Protease
treatment in 10 mL Buffer A overnight,
directly collect the ﬂow through
Elute with a linear gradient
(0.05–0.5 M) of NaCl
concentration in 40 mL
Elute with a linear gradient
(0.05–0.45 M) of NaCl
concentration in 8 mL
Elute with Buffer D
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ical isoenzyme FabZ (EC: 4.2.1.59) which widely represented in
other bacteria [11,17,18]. Currently, all of the resolved FabZ struc-
tures have similar hexametric hotdog fold structures, displaying a
classic ‘‘trimer of homodimer’’ organization [19–22]. Because of
the particular long substrate and failing to identify a speciﬁc
mycobacterial homologue by BLAST searches of E. coli FabA (EC:
4.2.1.59 and 5.3.3.14) [17], another typical member of hotdog fam-
ily [23], it seems possible that HadAB possesses new structural fea-
tures to execute dehydration process. Determination of the crystal
structure of HadAB would allow thorough understanding of the
differences and similarities between HadAB and FabZ and lay the
foundation for new anti-TB drug development.
In this work, because common or tandem expression could not
get enough protein with high purity and stability for crystalliza-
tion, a method for co-expression of the recombinant HadAB was
developed. The gene of HadA and HadB was cloned respectively
into different vectors, co-transformed into E. coli cells and the
enzyme HadAB complex was expressed. Then we described thepuriﬁcation, crystallization and preliminary X-ray diffraction anal-
ysis of HadAB from Mycobacterium tuberculosis. Our work provided
a particular method of protein complex expression and puriﬁcation
and laid the foundation for structure determination of HadAB and
more similar enzymic complexes.2. Materials and methods
In this work, we used pGEX-6p-1, Glutathione Sepharose resin,
HiTrap™ Q HP anion exchange column, RESOURCE™ Q anion
exchange column and Superdex 75 10/300 GL gel-ﬁltration column
from GE Healthcare (USA); pRSFDuet-1 from Novagen (USA); SDS
and isopropyl-b-d-thiogalactoside (IPTG) from Sigma (USA); tryp-
tone, yeast extract and protein standards for electrophoresis from
Thermo Fisher Scientiﬁc (USA); tris, glycine, DTT and Coomassie
G-250 and R-250 from Amresco (USA); ultraﬁltration equipment
from Millipore (USA); crystallization screening kits from
Hampton Research (USA); DNA extraction kit from QIAGEN
Fig. 2. SDS–PAGE analysis of HadAB during GST afﬁnity puriﬁcation. Lane 1, total
proteins after ﬂowing through from Glutathione Sepharose column; lane 2, the
bound proteins enriched on the column, the GST tagged HadAB complex was the
most; lane 3, the elution after Prescission Protease digestion overnight, the free
untagged HadAB complex was eluted; lane 4, the resin after elution showed that the
GST tag and the uncut GST-HadB were left on the column. This means the digestion
was uncompleted; lane 5, molecular weight standard markers. HadAB was run on
16% SDS–PAGE and stained with Coomassie R-250 to estimate its purity (similarly
hereinafter).
Fig. 3. SDS–PAGE analysis (inset) and elution proﬁle of HadAB during ion exchange
chromatography using a HiTrap™ Q HP anion exchange column (a) and a
RESOURCE™ Q anion exchange column (b). In (a), lane 1–7 depict samples from
elution volume 78.50–84.10 mL, 0.8 mL each; lane 8, sample between 84.9 and
85.7 mL; lane 9, sample between 86.5 and 87.3 mL. There are small amount of
impure proteins in the elution samples under the peak. Thus, HadAB is not very
pure. In (b), lane 1–9 depict samples from elution volume 105.4–107.2 mL, 0.2 mL
each. The purity of HadAB under the peak is improved by the second ion exchange
chromatography.
Fig. 4. SDS–PAGE analysis (inset) and elution proﬁle of HadAB during gel ﬁltration
chromatography using a Superdex 75 column. The well-shaped single peak means
the sample is homogenous. The ﬁnal purity of sample after gel ﬁltration as
estimated by SDS–PAGE was >95%.
Table 2




a, b, c (Å) a = b = 82.0, c = 139.8
a, b, c () a = b = c = 90.0
Wavelength (Å) 1.00000
Resolution (Å) 50.00–1.75 (1.81–1.75)a
Total observation 462,997
Unique reﬂections 48,837





a Values in parentheses are for the highest resolution shell.
b Rmerge = RhRi|Iih  hIhi|/RhRihIhi, where hIhi is the mean intensity of the obser-
vations of Iih of reﬂection h.
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sponding buffer solution from TaKaRa(China).
All other reagents were of high purity or reagent grade (China).
2.1. Molecular cloning
The Rv0635 gene encoding HadA was ampliﬁed fromM. tubercu-
losis H37Rv genomic DNA by using ExTaq polymerase (TaKaRa) as
well as the forward primer 50- TTCCATATGGTGGCGTTGA
GCGCAGACAT-30 and the reverse primer 50-CCGCTCGAGTCA
CGCAGCGCCATCAGAAA-30. NdeI and XhoI restriction sites are
underlined. Ampliﬁcation were carried out by a thermal cycler
(Bio-Rad) according to the following protocol: step 1, 95 C for
300 s; step 2, 94 C for 40 s; step 3, 60 C for 40 s; step 4, 72 C
for 32 s; repeat from step 2 for 30 cycles. The PCR products were
subjected to a ﬁnal ampliﬁcation step of 5 min at 72 C. They were
separated by horizontal electrophoresis in 1% agarose gel. The pro-
duct corresponding to HadA (about 500 bp) was extracted from the
gel using the DNA extraction kit (QIAGEN). Then the puriﬁed PCR
product was hydrolyzed with endonucleases NdeI and XhoI and
ligated according to the manufacturer’s protocol with expression
vector pRSFDuet-1 (Novagen), which was preliminarily treated
with the same endonucleases. The Rv0636 gene from the same
source which encodes HadB was PCR-ampliﬁed using primers
pBm_F (50-CGCGGATCCATGGCGCTGCGTGAGTTCAG-30) and pXh_R
(50-CCGCTCGAGCTACGCTAACTTCGCCGAGG-30). BamHI and XhoI
restriction sites are underlined. Ampliﬁcation protocol is the same
as HadA. After restriction digestion, the gene was ligated into the
Fig. 5. (a) Typical crystals of HadAB suitable for collecting diffraction images under
X-ray. (b) A typical X-ray diffraction image obtained from a crystal of HadAB
complex. Resolution rings were marked.
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pRSFDuet-1-HadA and pGEX-6p-1-HadB were co-transformed into
E. coli. BL21(DE3) for expression. Correct clone was screened by
bi-anti agar plate and PCR and conﬁrmed by DNA sequencing.2.2. Expression and puriﬁcation of HadAB
For expressionofGST-HadAB recombinant protein, the cellswere
grown aerobically at 37 C in 2 L Terriﬁc Broth medium with
100 lg mL1 ampicillin and 50 lg mL1 kanamycin. When the
OD600 reached 1.0, the culture was induced with 0.3 mM isoprop
yl-b-D-thiogalactopyranoside (IPTG, Sigma) and incubated at 16 C
for 18 h. Cells were harvested by centrifugation at 4200g for
30 min at 4 C and resuspended in 160 mL Buffer A (50 mM Tris–
HCl, pH 8.0, 300 mM NaCl, and 10% (v/v) glycerol). Suspension was
passed through the High voltage Homogenizer (AVESTIN
Company, EF-C3) for 4 times on ice, and the cells were lysed by the
high pressure at around 120 MPa [24]. The lysate was centrifuged
at 30,700g for 30 min at 4 C to remove unbroken cells and debris.
The supernatant was loaded onto a column with 2 mL Glutathione
Sepharose resin (GE Healthcare) pre-equilibrated with Buffer A.
The column was washed with 30–50 column volumes of Buffer A
to remove unbound proteins and then incubated in 10 mL Buffer Acontaining 30 lg mL1 Prescission Protease at 4 C overnight to
cut off GST tag. The next day, the ﬂow through containing the
untagged HadAB was collected, and desalted with six-fold dilusion
with Buffer B (50 mM Tris–HCl, pH 8.0, 50 mM NaCl and 10% (v/v)
glycerol). It was further puriﬁed using a 5 mL HiTrap™ Q HP anion
exchange column (GE Healthcare) with an AKTA puriﬁer (GE
Healthcare) machine at 16 C. The column was pre-equilibrated
with Buffer B and the protein sample was loaded onto the column
with 1.5 mL min1 ﬂow rate. After thorough washing with Buffer B
for 2–3 column volumes, protein bound to the column was eluted
with a linear gradient (0.05–0.5 M) of NaCl concentration in 8 col-
umn volumes with 1.5 mL min1 ﬂow rate. The linear gradient of
NaCl concentration was created by mixing Buffer B and Buffer C
(50 mM Tris–HCl, pH 8.0, 1 M NaCl and 10% (v/v) glycerol) by
AKTA puriﬁer machine. Fractions containing protein were analyzed
bySDS–PAGE. Concentration of the separating gel and concentrating
gel was 16% and 4%, respectively. Gels were stainedwith Coomassie
R-250. Those fractions that contained pure target protein were
pooled, desalted with Buffer B and then further puriﬁed by using a
1 mL RESOURCE™ Q anion exchange column (GE Healthcare).
After processing in the same way, the pure target protein was
pooled, concentrated to a volume less than 500 lL and injected into
a 24 mL Superdex™ 75 10/300 GL gel-ﬁltration column (GE
Healthcare) pre-equilibrated with Buffer D (50 mM Tris–HCl, pH
8.0, 150 mM NaCl, and 10% (v/v) glycerol). The protein sample was
eluted with 0.5 mL min1 ﬂow rate and collected by fractions.
After SDS–PAGE analysis, fractions containing pure and homoge-
nous HadAB was pooled and concentrated by ultraﬁltration using
Amicon centrifugal device (Millipore). The protein concentration
was calculated by measuring the sample absorbance at 280 nm
and adjusting with its extinction coefﬁcient of 1.15. Puriﬁed
HadAB was ﬁnally concentrated to 10 mg mL1 for crystallization
trials. ThepuriﬁcationconditionsofHadAB in each stepwas summa-
rized in Table 1.
2.3. Crystallization
Initial crystallization screening was carried out at 16 C by the
hanging-drop vapor-diffusion method in 96-well plates
(XtalQuest) using a Mosquito™ liquid-handling system (TPP
Labtech). Each hanging drop was set up by mixing 200 nL protein
solution (10 mg mL1) with 200 nL reservoir solution. The reser-
voir solutions were from commercially available crystallization
screening kits (Index, SaltRx, PEG/Ion, PEG/Ion 2, Crystal Screen,
Crystal Screen 2 and Natrix; Hampton Research). Crystals appeared
in several conditions after a few days. Subsequent optimizations
were carried out by varying the variety and concentration of poly-
ethylene glycol (PEG), protein concentration and the pH of the
reservoir solution. Final optimized crystals for data collection were
obtained from a condition consisting of 6 mg mL1 protein, 26%
(w/v) PEG 4000, 100 mM HEPES, pH7.5.
2.4. Data collection and processing
Data collection was performed at 100 K on beamline BL17U at
Shanghai Synchrotron Radiation Facility (SSRF) after crystals were
soaked in the reservoir solution supplemented with 20% (v/v) glyc-
erol for 10 s and ﬂash frozen in liquid nitrogen. Crystals diffracted
X-rays to 1.75 Å resolution and a data set was collected. HKL2000
[25] software was used for data processing.3. Results and discussion
Our previous work indicated that, when HadB was expressed
alone, most of the His-tagged product was inclusion body, and
Y. Dong et al. / Protein Expression and Puriﬁcation 114 (2015) 115–120 119the puriﬁed protein was relatively unstable in solution.
Meanwhile, although HadAB complex could be obtained by a tan-
dem expression method, we were unable to get high quality crys-
tals from this sample by reason of the His-tag fused onto HadA. To
improve our sample, co-expression was performed for GST tagged
HadB and none tagged HadA. Purer HadAB complex was success-
fully overexpressed in E. coli and obtained. It is more conducive
to crystallization and qualiﬁed diffraction data collection.
After expression, the protein was puriﬁed to homogeneity by
utilizing a series of chromatographic techniques which included
GST afﬁnity puriﬁcation at ﬁrst using a Glutathione Sepharose col-
umn (GE Healthcare), ion exchange chromatography next using a
HiTrap Q HP and a Resource Q anion-exchange column (GE
Healthcare) and size-exclusion chromatography ﬁnally using a
Superdex 75 10/300 GL gel ﬁltration column (GE Healthcare).
GST afﬁnity chromatography could remove most of impure pro-
teins. However, this process will lose a lot of target protein because
of insufﬁcient Prescission Protease digestion (Fig. 2). After two
kinds of anion exchange chromatography puriﬁcation, redundant
HadA and most of the molecular chaperone could be separated
(Fig. 3a and b). If either HiTrap™ Q HP or RESOURCE™ Q was used,
even twice, puriﬁcation effect will be reduced. Remarkably, the
HadAB complex elution performed as a perfect single peak during
gel ﬁltration chromatography (Fig. 4). The ﬁnal purity of sample
after gel ﬁltration as estimated by SDS–PAGE was >95%. An equal
molar ratio of HadA and HadB for complex formation could be
deduced from SDS–PAGE as well (Fig. 4). An elution peak volume
of 9.3 mL corresponded to an approximate molecular mass of
65 kDa based on calibration of the column using standard molecu-
lar weight markers. Given the theoretical molecular weight of
HadAB complex is 32.5 kDa, our result indicated that HadAB exists
as a tetramer at 16 C.
After initial crystallization screening, crystals were obtained in
one of the conditions consisting of 22% (w/v) PEG 3000, 100 mM
HEPES, pH7.5 after 2 days of incubation at 16 C. After multiple
optimization of crystallization conditions, crystals grew up to
50 lm (Fig. 5a). This crystal diffracted X-rays to 1.75 Å resolution
on beamline BL17U at SSRF (Shanghai, China) (Fig. 5b). A data set
was collected and the statistics of data collection are listed in
Table 2. The crystal belonged to space group P41212, with
unit-cell parameters a = b = 82.0 Å, c = 139.8 Å, a = b = c = 90.0. A
Matthews coefﬁcient of 3.56 Å3 Da1 [26,27], corresponding to a
solvent content of 65.49%, indicated the presence of both one
molecule of HadA and HadB per asymmetric unit.
In subsequent studies, an anomalous data set collected using
crystals of selenomethionine labeled HadAB was used for phasing
by single-wavelength anomalous diffraction (SAD) method. A total
of four selenium sites were located by SHELX program suit [28] and
the phase was solved. A density map was created by using intensi-
ties in the collected data and the solved phase. The 3D structural
model of HadAB was built according to the density and reﬁnement
is currently in progress. Expectingly, the crystal structure of HadAB
will help us understand the mechanism of substrate dehydration
as well as biosynthesis of mycolic acids, and also lay the foundation
for anti-TB drug discovery.Conﬂict of interest
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